Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
Wednesday, March 12, 2025Hansa Biopharma AB Hansa announced today that it has completed enrolment of its HMedIdeS Post Authorization Efficacy and Safety PAES study an openlabel Phase confirmatory study in Europe investigating the oneyear patient and graft survival in highly...
Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV
Wednesday, March 12, 2025Gilead Sciences announced a significant milestone the US FDA accepted their New Drug Applications NDAs for lenacapavir LEN a groundbreaking twiceyearly injectable HIV capsid inhibitor for preexposure prophylaxis PrEP The FDA granted priority review w...
Updates on Influenza Vaccine Strain Recommended by WHO (2025-2026 Northern Hemisphere)
Wednesday, March 12, 2025To maintain vaccine efficacy WHO regularly updates influenza vaccine strains based on global epidemiological virological and serological analyses On February WHO announced the recommended strains for the northern hemisphere influenza season
Valo Therapeutics announces EUR 19m of investment funding and expanded clinical trials
Tuesday, March 11, 2025Valo Therapeutics Oy announces that it has successfully secured a financing round of million part of which was raised in Europe and part in Australia to clinically develop its innovative immune therapy for cancer
PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands
Tuesday, March 11, 2025PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of novel MDXX class molecules including its LaNeo MDMA is excited to announce that it has signed a distribution agreement with Duchefa Farma B...
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
Monday, March 10, 2025Bristol Myers Squibb announced that the European Commission EC has approved Opdivo nivolumab plus Yervoy ipilimumab for the firstline treatment of adult patients with unresectable or advanced hepatocellular carcinoma HCC
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Monday, March 10, 2025Today Novo Nordisk announced headline results from REDEFINE a phase trial in the global REDEFINE programme REDEFINE is a week efficacy and safety trial investigating onceweekly subcutaneous CagriSema a fixed dose combination of cagrilintide mg an...
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
Friday, March 07, 2025Roche announced today the launch of the Roche Genentech Innovation Center Boston at Harvards Enterprise Research Campus in Allston which will further strengthen the longstanding partnership in areas such as disease biology engineering and artificial...
Atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
Thursday, March 06, 2025Atai Life Sciences a clinicalstage biopharmaceutical company aiming to transform the treatment of mental health disorders today announced the completion of patient enrollment in the eightweek doubleblind core stage of the global Phase b clinical tria...
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Thursday, March 06, 2025Ascentage Pharma a global biopharmaceutical company engaged in discovering developing and commercializing therapies to address global unmet medical needs primarily for hematological malignancies today announced that its drug olverembatinib has been g...
